CYP 2.50% 19.5¢ cynata therapeutics limited

pathophysiology of severe COVID -19 (1) ARDSThe primary...

  1. 174 Posts.
    lightbulb Created with Sketch. 85
    pathophysiology of severe COVID -19

    (1) ARDS
    The primary pathology is ARDS, characterized by diffuse alveolar damage (e.g. including hyaline membranes). Pneumocytes with viral cytopathic effect are seen, implying direct virus damage (rather than a purely hyper-inflammatory injury; Xu et al 2/17).

    ( 2) Cytokine storm
    Emerging evidence suggests that some patients may respond to COVID-19 with an exuberant “cytokine storm” reaction (with features of bacterial sepsis or hemophagocytic lymphohistiocytosis). Clinical markers of this may include elevations of C-reactive protein and ferritin, which appear to track with disease severity and mortality (Ruan 3/3/20).

    So this is the two pathological process that cause death from COVID - 19

    Pick up the phone Ross and don’t put it down. There is massive opportunity here. make sure every ICU in Austrlia, England, the world is aware of CYPs off the shelf stem cells. They are proven safe already, they have bench studies in sepsis, cytokine release and ARDS! ...the Chinese are running trials.... with what? if the ICUs are filling, and ECMO utilisation is at capacity, CYP could have a potential treatment. Even if there was 10% response rate.... this should be shouted from the roof right now. If the greater market got a hint of this, it could be huge.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
19.5¢
Change
-0.005(2.50%)
Mkt cap ! $35.20M
Open High Low Value Volume
21.0¢ 21.0¢ 19.5¢ $18.97K 94.53K

Buyers (Bids)

No. Vol. Price($)
1 4999 19.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 10000 1
View Market Depth
Last trade - 16.10pm 06/08/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.